Acute HIV infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute HIV infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on HIV Treatment Interruption in Children with Perinatal HIV Using Lamivudine and Drug Combination https://clinicaltrials.eu/trial/study-on-hiv-treatment-interruption-in-children-with-perinatal-hiv-using-lamivudine-and-drug-combination/ Wed, 29 Apr 2026 15:03:21 +0000 https://clinicaltrials.eu/trial/study-on-hiv-treatment-interruption-in-children-with-perinatal-hiv-using-lamivudine-and-drug-combination/ This clinical trial is focused on studying the treatment of HIV, specifically in individuals who acquired the infection at birth. The study will explore various medications used in antiretroviral therapy, which is a treatment designed to manage HIV infection. The medications being studied include Lamivudine, Darunavir, Cobicistat (also known as GS-9350), Emtricitabine, Tenofovir Alafenamide, Dolutegravir (also known as GSK1349572), Rilpivirine (also known as TMC278), Abacavir, and Bictegravir (also known as GS-9883). Some participants will receive a placebo as part of the study.

The purpose of the study is to understand how the HIV virus behaves in the body and to find new ways to manage the infection by temporarily stopping antiretroviral therapy. This is done to see if the virus remains under control without continuous medication. The study will involve monitoring the virus and the immune system’s response during this period. Participants will be selected based on specific criteria, and their health will be closely monitored throughout the study.

The study will last for a period of up to 48 weeks, during which participants will undergo regular check-ups and tests to assess the effects of stopping and restarting their medication. The goal is to gather information that could lead to better treatment strategies for managing HIV in the future. Participants will be carefully monitored to ensure their safety and well-being throughout the study.

]]> Study on the Effectiveness of 10-1074-LS and Teropavimab in Controlling HIV in Patients with Early Stage HIV Infection https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-10-1074-ls-and-teropavimab-in-controlling-hiv-in-patients-with-early-stage-hiv-infection/ Wed, 29 Apr 2026 15:03:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-10-1074-ls-and-teropavimab-in-controlling-hiv-in-patients-with-early-stage-hiv-infection/ The RIO Trial is focused on studying the treatment of HIV, a virus that attacks the body’s immune system. The study is investigating the effectiveness of two specific medications, 10-1074-LS and 3BNC117-LS, which are types of proteins known as broadly neutralizing antibodies. These antibodies are designed to help control the virus in people who have been recently diagnosed with HIV and are already receiving standard treatment. The trial will compare the effects of these antibodies with a placebo to see if they can help maintain control of the virus without the need for ongoing standard treatment.

Participants in the study will receive either the antibody treatment or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study aims to observe how well the antibodies work in keeping the virus under control over a period of 20 weeks after stopping standard treatment. The trial will also monitor the safety of the treatment by checking for any side effects or adverse reactions.

Throughout the study, participants will have regular check-ups to measure their immune system’s response, including the levels of CD4 T cells, which are a type of white blood cell important for fighting infections. The study will also track how long the virus remains undetectable in the blood and how quickly it returns if it does. The goal is to understand if these antibodies can provide a new way to manage HIV without continuous medication.

]]>